Macrophage depletion ameliorates nephritis induced by pathogenic antibodies

Journal of Autoimmunity

Volumn 57, Issue , 2015, Pages 42-52

  Chalmers, Samantha A ^a   Chitu, Violeta ^a   Herlitz, Leal C ^b   Sahu, Ranjit ^c   Stanley, E Richard ^a   Putterman, Chaim ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NewYork Presbyterian Columbia University Irving Medical Center   (United States)

^c FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

Lupus nephritis; Macrophages; Nephrotoxic serum nephritis (NTS); SLE

Indexed keywords

ANTIBODY; AUTOANTIBODY; CREATININE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GW 2580; INDUCIBLE NITRIC OXIDE SYNTHASE; PHOSPHOTRANSFERASE INHIBITOR; RANTES; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; 5-(3-METHOXY-4-((4-METHOXYBENZYL)OXY)BENZYL)PYRIMIDINE-2,4-DIAMINE; ANISOLE DERIVATIVE; GELATINASE B; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN G; PYRIMIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; CELL SUSPENSION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; EXPERIMENTAL AUTOIMMUNE GLOMERULONEPHRITIS; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GLOMERULUS; HEMATOPOIESIS; IMMUNE COMPLEX DISEASE; IMMUNOFLUORESCENCE; IMMUNOPATHOGENESIS; LUPUS ERYTHEMATOSUS NEPHRITIS; MACROPHAGE; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; QUANTITATIVE ANALYSIS; UREA NITROGEN BLOOD LEVEL; ANIMAL; C57BL MOUSE; DBA MOUSE; DISEASE MODEL; DRUG EFFECTS; GENETICS; GLOMERULONEPHRITIS; HUMAN; IMMUNOLOGY; KIDNEY; LUPUS NEPHRITIS; METABOLISM; PATHOLOGY; RABBIT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE;

ANIMALS; ANISOLES; ANTIBODIES; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; GENE EXPRESSION; GLOMERULONEPHRITIS; HMGB1 PROTEIN; HUMANS; IMMUNOGLOBULIN G; KIDNEY; KIDNEY GLOMERULUS; LUPUS NEPHRITIS; MACROPHAGES; MATRIX METALLOPROTEINASE 9; MICE, INBRED C57BL; MICE, INBRED DBA; PROTEINURIA; PYRIMIDINES; RABBITS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES;

EID: 84922791242     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2014.11.007     Document Type: Article

References (48)

1. Bethunaickan R., Sahu R., Davidson A. Analysis of renal mononuclear phagocytes in murine models of SLE. Methods Mol Biol 2012, 900:207-232.
2. Wynn T.A., Chawla A., Pollard J.W. Macrophage biology in development, homeostasis and disease. Nature 2013, 496:445-455.
3. Hume D.A. Macrophages as APC and the dendritic cell myth. JImmunol 2008, 181:5829-5835.
4. Yona S., Kim K.W., Wolf Y., Mildner A., Varol D., Breker M., et al. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity 2013, 38:79-91.
5. Geissmann F., Jung S., Littman D.R. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 2003, 19:71-82.
6. Hill G.S., Delahousse M., Nochy D., Rémy P., Mignon F., Méry J.P., et al. Predictive power of the second renal biopsy in lupus nephritis: significance of macrophages. Kidney Int 2001, 59:304-316.
7. Schiffer L., Bethunaickan R., Ramanujam M., Huang W., Schiffer M., Tao H., et al. Activated renal macrophages are markers of disease onset and disease remission in lupus nephritis. JImmunol 2008, 180:1938-1947.
8. Sahu R., Bethunaickan R., Singh S., Davidson A. Structure and function of renal macrophages and dendritic cells from lupus-prone mice. Arthritis Rheumatol 2014, 66:1596-1607.
9. Hasegawa H., Kohno M., Sasaki M., Inoue A., Ito M.R., Terada M., et al. Antagonist of monocyte chemoattractant protein 1 ameliorates the initiation and progression of lupus nephritis and renal vasculitis in MRL/lpr mice. Arthritis Rheum 2003, 48:2555-2566.
10. Shimizu S., Nakashima H., Masutani K., Inoue Y., Miyake K., Akahoshi M., et al. Anti-monocyte chemoattractant protein-1 gene therapy attenuates nephritis in MRL/lpr mice. Rheumatol (Oxford) 2004, 43:1121-1128.
11. Viedt C., Dechend R., Fei J., Hänsch G.M., Kreuzer J., Orth S.R. MCP-1 induces inflammatory activation of human tubular epithelial cells: involvement of the transcription factors, nuclear factor-kappaB and activating protein-1. JAm Soc Nephrol 2002, 13:1534-1547.
12. Denny M.F., Chandaroy P., Killen P.D., Caricchio R., Lewis E.E., Richardson B.C., et al. Accelerated macrophage apoptosis induces autoantibody formation and organ damage in systemic lupus erythematosus. JImmunol 2006, 176:2095-2104.
13. Lenda D.M., Kikawada E., Stanley E.R., Kelley V.R. Reduced macrophage recruitment, proliferation, and activation in colony-stimulating factor-1-deficient mice results in decreased tubular apoptosis during renal inflammation. JImmunol 2003, 170:3254-3262.
14. Lenda D.M., Stanley E.R., Kelley V.R. Negative role of colony-stimulating factor-1 in macrophage, T cell, and B cell mediated autoimmune disease in MRL-Fas(lpr) mice. JImmunol 2004, 173:4744-4754.
15. Du Y., Fu Y., Mohan C. Experimental anti-GBM nephritis as an analytical tool for studying spontaneous lupus nephritis. Arch Immunol Ther Exp (Warsz) 2008, 56:31-40.
16. Perry D., Sang A., Yin Y., Zheng Y.Y., Morel L. Murine models of systemic lupus erythematosus. JBiomed Biotechnol 2011, 2011:271694.
17. Conway J.G., McDonald B., Parham J., Keith B., Rusnak D.W., Shaw E., et al. Inhibition of colony-stimulating-factor-1 signaling invivo with the orally bioavailable cFMS kinase inhibitor GW2580. Proc Natl Acad Sci U S A 2005, 102:16078-16083.
18. Guilbert L.J., Stanley E.R. Specific interaction of murine colony-stimulating factor with mononuclear phagocytic cells. JCell Biol 1980, 85:153-159.
19. Byrne P.V., Guilbert L.J., Stanley E.R. Distribution of cells bearing receptors for a colony-stimulating factor (CSF-1) in murine tissues. JCell Biol 1981, 91:848-853.
20. Stanley E.R., Chitu V. CSF-1 receptor signaling in Myeloid cells. Cold Spring Harb Perspect Biol 2014, 6.
21. Karaman M.W., Herrgard S., Treiber D.K., Gallant P., Atteridge C.E., Campbell B.T., et al. Aquantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008, 26:127-132.
22. Dai X.M., Ryan G.R., Hapel A.J., Dominguez M.G., Russell R.G., Kapp S., et al. Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects. Blood 2002, 99:111-120.
23. Chitu V., Stanley E.R. Colony-stimulating factor-1 in immunity and inflammation. Curr Opin Immunol 2006, 18:39-48.
24. Wei S., Lightwood D., Ladyman H., Cross S., Neale H., Griffiths M., et al. Modulation of CSF-1-regulated post-natal development with anti-CSF-1 antibody. Immunobiology 2005, 210:109-119.
25. Xia Y., Campbell S.R., Broder A., Herlitz L., Abadi M., Wu P., et al. Inhibition of the TWEAK/Fn14 pathway attenuates renal disease in nephrotoxic serum nephritis. Clin Immunol 2012, 145:108-121.
26. Gaynor B., Putterman C., Valadon P., Spatz L., Scharff M.D., Diamond B. Peptide inhibition of glomerular deposition of an anti-DNA antibody. Proc Natl Acad Sci U S A 1997, 94:1955-1960.
27. Chitu V., Ferguson P.J., de Bruijn R., Schlueter A.J., Ochoa L.A., Waldschmidt T.J., et al. Primed innate immunity leads to autoinflammatory disease in PSTPIP2-deficient cmo mice. Blood 2009, 114:2497-2505.
28. Wen J., Xia Y., Stock A., Michaelson J.S., Burkly L.C., Gulinello M., et al. Neuropsychiatric disease in murine lupus is dependent on the TWEAK/Fn14 pathway. JAutoimmun 2013, 43:44-54.
29. Laskin D.L., Sunil V.R., Gardner C.R., Laskin J.D. Macrophages and tissue injury: agents of defense or destruction?. Annu Rev Pharmacol Toxicol 2011, 51:267-288.
30. Ram M., Sherer Y., Shoenfeld Y. Matrix metalloproteinase-9 and autoimmune diseases. JClin Immunol 2006, 26:299-307.
31. Moreno J.A., Sastre C., Madrigal-Matute J., Muñoz-García B., Ortega L., Burkly L.C., et al. HMGB1 expression and secretion are increased via TWEAK-Fn14 interaction in atherosclerotic plaques and cultured monocytes. Arterioscler Thromb Vasc Biol 2013, 33:612-620.
32. Kim S.H., Kang Y.J., Kim W.J., Woo D.K., Lee Y., Kim D.I., et al. TWEAK can induce pro-inflammatory cytokines and matrix metalloproteinase-9 in macrophages. Circ J 2004, 68:396-399.
33. Bomback A.S., Appel G.B. Updates on the treatment of lupus nephritis. JAm Soc Nephrol 2010, 21:2028-2035.
34. Viedt C., Orth S.R. Monocyte chemoattractant protein-1 (MCP-1) in the kidney: does it more than simply attract monocytes?. Nephrol Dial Transpl 2002, 17:2043-2047.
35. Pollard J.W. Trophic macrophages in development and disease. Nat Rev Immunol 2009, 9:259-270.
36. Nandi S., Gokhan S., Dai X.M., Wei S., Enikolopov G., Lin H., et al. The CSF-1 receptor ligands IL-34 and CSF-1 exhibit distinct developmental brain expression patterns and regulate neural progenitor cell maintenance and maturation. Dev Biol 2012, 367:100-113.
37. Yamane F., Nishikawa Y., Matsui K., Asakura M., Iwasaki E., Watanabe K., et al. CSF-1 receptor-mediated differentiation of a new type of monocytic cell with B cell-stimulating activity: its selective dependence on IL-34. JLeukoc Biol 2014, 95:19-31.
38. Han Y., Ma F.Y., Tesch G.H., Manthey C.L., Nikolic-Paterson D.J. c-fms blockade reverses glomerular macrophage infiltration and halts development of crescentic anti-GBM glomerulonephritis in the rat. Lab Invest 2011, 91:978-991.
39. Ikezumi Y., Hurst L.A., Masaki T., Atkins R.C., Nikolic-Paterson D.J. Adoptive transfer studies demonstrate that macrophages can induce proteinuria and mesangial cell proliferation. Kidney Int 2003, 63:83-95.
40. Eddy A.A., McCulloch L.M., Adams J.A. Intraglomerular leukocyte recruitment during nephrotoxic serum nephritis in rats. Clin Immunol Immunopathol 1990, 57:441-458.
41. Conway J.G., Pink H., Bergquist M.L., Han B., Depee S., Tadepalli S., et al. Effects of the cFMS kinase inhibitor 5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine (GW2580) in normal and arthritic rats. JPharmacol Exp Ther 2008, 326:41-50.
42. Pixley F.J. Macrophage migration and its regulation by CSF-1. Int J Cell Biol 2012, 2012:501962.
43. Tveita A.A., Rekvig O.P., Zykova S.N. Increased glomerular matrix metalloproteinase activity in murine lupus nephritis. Kidney Int 2008, 74:1150-1158.
44. Bethunaickan R., Berthier C.C., Ramanujam M., Sahu R., Zhang W., Sun Y., et al. Aunique hybrid renal mononuclear phagocyte activation phenotype in murine systemic lupus erythematosus nephritis. JImmunol 2011, 186:4994-5003.
45. Chang Y.H., Lin I.L., Tsay G.J., Yang S.C., Yang T.P., Ho K.T., et al. Elevated circulatory MMP-2 and MMP-9 levels and activities in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Biochem 2008, 41:955-959.
46. Pisetsky D.S. HMGB1: a smoking gun in lupus nephritis?. Arthritis Res Ther 2012, 14:112.
47. Abdulahad D.A., Westra J., Bijzet J., Dolff S., van Dijk M.C., Limburg P.C., et al. Urine levels of HMGB1 in Systemic Lupus Erythematosus patients with and without renal manifestations. Arthritis Res Ther 2012, 14:R184.
48. Qing X., Pitashny M., Thomas D.B., Barrat F.J., Hogarth M.P., Putterman C. Pathogenic anti-DNA antibodies modulate gene expression in mesangial cells: involvement of HMGB1 in anti-DNA antibody-induced renal injury. Immunol Lett 2008, 121:61-73.